According to Alkermes's latest financial reports the company has a price-to-book ratio of 3.47.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 3.85 | -6.43% |
2022-12-31 | 4.11 | 21.68% |
2021-12-31 | 3.38 | 13.61% |
2020-12-31 | 2.98 | 0.35% |
2019-12-31 | 2.97 | -24.44% |
2018-12-31 | 3.92 | -43.92% |
2017-12-31 | 7.00 | 0.19% |
2016-12-31 | 6.98 | -23.27% |
2015-12-31 | 9.10 | 47.16% |
2014-12-31 | 6.19 | 12.27% |
2013-12-31 | 5.51 | 106.66% |
2012-12-31 | 2.67 | 7.23% |
2011-12-31 | 2.49 | -15.83% |
2010-12-31 | 2.95 | 39.37% |
2009-12-31 | 2.12 | -5.99% |
2008-12-31 | 2.25 | -44.57% |
2007-12-31 | 4.07 | -42.08% |
2006-12-31 | 7.02 | -91.14% |
2005-12-31 | 79.3 | 17.35% |
2004-12-31 | 67.6 | 455.15% |
2003-12-31 | 12.2 | 74.58% |
2002-12-31 | 6.97 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.20 | 50.09% | ๐บ๐ธ USA |
Novartis NVS | 4.30 | 24.08% | ๐จ๐ญ Switzerland |
Pfizer PFE | 1.67 | -51.95% | ๐บ๐ธ USA |
Sanofi SNY | 1.42 | -59.18% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | 3.36 | -3.14% | ๐บ๐ธ USA |
AstraZeneca AZN | 5.64 | 62.54% | ๐ฌ๐ง UK |
Acorda Therapeutics
ACOR | 0.0139 | -99.60% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 1.81 | -47.70% | ๐ฎ๐ฑ Israel |